Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UNC5B antisense RNA 1 (UNC5B-AS1) is a long non-coding RNA (lncRNA), 647 base pairs in length and composed of two exons, located as an antisense transcript to the intron 1 of the UNC5B gene. It is also known as UASR1 or TP53LC05. This RNA molecule does not encode a protein, but instead modulates gene expression through several mechanisms, including acting as a competing endogenous RNA (ceRNA) that sequesters microRNAs. UNC5B-AS1 is upregulated in a variety of cancers (notably breast, ovarian, liver, and glioblastoma), where it can promote or suppress cancer cell proliferation, migration, and epithelial-mesenchymal transition depending on cellular context. Its actions are mediated via signaling pathways such as AKT/mTOR or by modulating miRNA-targeted genes (e.g., sponging miR-4306 in hepatocellular carcinoma or miR-24-3p in glioblastoma). UNC5B-AS1 is being explored as an oncogenic marker and a potential prognostic biomarker in several malignancies, but is not a therapeutic target in the classical sense (such as a receptor or enzyme), and no drugs are directed against it[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UNC5B antisense RNA 1 (UNC5B-AS1).